Global Market Direct’s pharmaceuticals report, “Aradigm Corporation - Product Pipeline Review - 2013” provides data on the Aradigm Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Aradigm Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Aradigm Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.
- Aradigm Corporation - Brief Aradigm Corporation overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Aradigm Corporation human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Aradigm Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Aradigm Corporation’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Aradigm Corporation’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Aradigm Corporation in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Aradigm Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Aradigm Corporation. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Aradigm Corporation and identify potential opportunities in those areas.
Table Of Contents
Aradigm Corporation - Product Pipeline Review - 2013 Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Aradigm Corporation Snapshot 4 Aradigm Corporation Overview 4 Key Information 4 Key Facts 4 Aradigm Corporation - Research and Development Overview 5 Key Therapeutic Areas 5 Aradigm Corporation - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Aradigm Corporation - Pipeline Products Glance 9 Aradigm Corporation Clinical Stage Pipeline Products 9 Phase I Products/Combination Treatment Modalities 9 Aradigm Corporation - Early Stage Pipeline Products 10 Pre-Clinical Products/Combination Treatment Modalities 10 Aradigm Corporation - Drug Profiles 11 ARD-1600 11 Product Description 11 Mechanism of Action 11 RandD Progress 11 ciprofloxacin Liposomal 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 Aradigm Corporation - Pipeline Products by Route of Administration 13 Aradigm Corporation - Pipeline Products By Mechanism of Action 14 Aradigm Corporation - Dormant Projects 15 Aradigm Corporation - Discontinued Pipeline Products 16 Aradigm Corporation - Company Statement 17 Aradigm Corporation - Locations And Subsidiaries 19 Head Office 19 Appendix 20 Methodology 20 Coverage 20 Secondary Research 20 Primary Research 20 Expert Panel Validation 20 Contact Us 21 Disclaimer 21
List of Tables
Aradigm Corporation, Key Information 4 Aradigm Corporation, Key Facts 4 Aradigm Corporation - Pipeline by Indication, 2013 6 Aradigm Corporation - Pipeline by Stage of Development, 2013 7 Aradigm Corporation - Monotherapy Products in Pipeline, 2013 8 Aradigm Corporation - Phase I, 2013 9 Aradigm Corporation - Pre-Clinical, 2013 10 Aradigm Corporation - Pipeline By Route of Administration, 2013 13 Aradigm Corporation - Pipeline Products By Mechanism of Action, 2013 14 Aradigm Corporation - Dormant Developmental Projects,2013 15 Aradigm Corporation - Discontinued Pipeline Products, 2013 16
List of Figures
Aradigm Corporation - Pipeline by Indication, 2013 6 Aradigm Corporation - Pipeline by Stage of Development, 2013 7 Aradigm Corporation - Monotherapy Products in Pipeline, 2013 8 Aradigm Corporation - Pipeline Products By Mechanism of Action, 2013 14